Tempus AI, Inc. (NASDAQ: TEM) continues to draw significant attention from the health technology and artificial intelligence investment sectors. As of the market close on April 22, 2026, the stock price for Tempus AI stood at $55.51. This valuation reflects a complex interplay between the company's aggressive expansion in precision medicine and the volatile nature of AI-driven healthcare stocks.

Current Trading Data for Tempus AI (TEM)

Understanding the current market standing of Tempus AI requires looking beyond the immediate ticker price. The following data points summarize the stock's position as of late April 2026:

  • Ticker Symbol: TEM
  • Primary Exchange: NASDAQ
  • Current Price: $55.51 (as of April 22, 2026)
  • Intraday Range: $52.91 – $58.04
  • 52-Week Range: $41.67 – $104.32
  • Market Capitalization: Approximately $9.96 billion
  • Average Daily Volume (30-day): 5.73 million shares

The stock's performance over the last month shows a recovery trend, with a gain of approximately 14.75%, despite a year-to-date return that remains negative at -13.90%. This volatility is characteristic of companies operating at the intersection of high-growth technology and regulated medical diagnostics.

Historical Performance from IPO to 2026

Tempus AI transitioned to the public market on June 14, 2024. The initial public offering (IPO) was priced at $37.00 per share, which valued the company at a premium during a period of intense interest in generative AI applications. Since its debut, the stock has experienced significant fluctuations.

In late 2025, the stock reached a historical high of $104.32, driven by optimism regarding the company's "Lens" software application and its ability to monetize one of the world's largest libraries of clinical and molecular data. However, as interest rates and market sentiment shifted towards profitability rather than raw growth, the stock retracted, finding strong support in the $40 to $50 range in early 2026.

Analyzing Tempus AI Financial Reports and Revenue Streams

The financial health of Tempus AI is defined by rapid top-line growth coupled with ongoing investments in infrastructure and R&D. According to the fiscal year 2025 results, the company reported a total revenue of $1.271 billion, a substantial increase from $693 million in 2024.

Quarterly Performance Analysis

In the fourth quarter of 2025 (ended December 31, 2025), Tempus reported:

  • Revenue: $367.21 million, representing an 82.98% year-over-year growth.
  • Gross Profit: $329 million, benefiting from improved efficiencies in lab diagnostics.
  • Net Income: A loss of $54.17 million. While still in the red, this was a notable narrowing compared to previous quarters when adjusted for stock-based compensation and one-time IPO-related expenses.
  • EBITDA: -$20.42 million, showing progress toward break-even status.

The company’s ability to sustain an 80%+ revenue growth rate has been a primary driver for the stock price's resilience. Investors are particularly focused on the "Diagnostics" segment, which includes Next-Generation Sequencing (NGS) and pharmacogenomic testing, as these areas provide recurring revenue streams.

The Impact of AI Healthcare Integration on Market Valuation

Tempus AI distinguishes itself from traditional diagnostic labs by operating as a technology-first entity. Its proprietary platform uses generative AI to analyze multimodal data—combining clinical records, imaging, and genomic profiles—to assist physicians in personalizing patient care.

The "Tempus Hub" and "Tempus Lens" products are critical to its valuation. Hub serves as a clinical application for providers, while Lens provides life sciences companies with research tools. The integration of AI into these platforms allows for "intelligent diagnostics," which can predict patient responses to specific therapies with higher accuracy than traditional methods.

Market analysts suggest that the premium valuation of TEM (currently trading at a significant price-to-book ratio) is justified by its data moat. With over 7 million clinical records and partnerships with roughly 50% of U.S. oncologists, the barrier to entry for competitors is exceptionally high.

Strategic Collaborations and Growth Drivers

Expansion through partnership has been a cornerstone of the Tempus strategy. Recently, in March 2026, the company expanded its collaboration with Merck to enhance precision medicine biomarker discovery. Such partnerships with major pharmaceutical players validate the utility of the Tempus data library and provide a steady influx of high-margin research revenue.

Key growth drivers to watch in the coming quarters include:

  1. Cardiology and Neurology Expansion: While oncology remains the core business, Tempus is aggressively moving into cardiovascular diagnostics and pharmacogenomics for depression.
  2. International Scaling: Recent listings on secondary exchanges like Euronext indicate an intent to capture European market share and broaden the investor base.
  3. AI Regulatory Clearances: Continued FDA clearances for AI-assisted diagnostic tools will likely act as positive catalysts for the stock price.

Potential Risks and Investment Considerations

Despite the robust growth, several risks could impact the Tempus stock price in the near term:

  • Path to Profitability: The company continues to operate at a net loss. While revenue is growing, the timeline for consistent positive net income remains a point of debate among analysts.
  • Data Privacy Regulations: As a health data company, Tempus is subject to stringent HIPAA and international data protection laws. Any regulatory shift or data breach could have catastrophic effects on its valuation.
  • Competitive Landscape: Established tech giants and specialized biotech firms are increasingly entering the AI diagnostics space, potentially putting pressure on margins.

Summary of Tempus Stock Performance

The Tempus AI (TEM) stock price, currently at $55.51, reflects a company in a high-growth phase within a transformative industry. While the 52-week volatility shows the risks inherent in the tech-heavy healthcare sector, the company's 2025 revenue of $1.27 billion and its narrowing losses suggest a maturing business model. For investors, the stock represents a play on the long-term convergence of artificial intelligence and personalized medicine.

FAQ about Tempus AI (TEM) Stock

What is the ticker symbol for Tempus AI?

The ticker symbol for Tempus AI is TEM, and it is traded on the NASDAQ exchange. It should not be confused with Tempus Resources (TMRFF), which is a separate entity in the mining sector.

Who founded Tempus AI and when did it go public?

Tempus AI was founded in 2015 by Eric Lefkofsky. The company went public on June 14, 2024, at an initial price of $37.00 per share.

What factors influence the Tempus stock price?

The stock price is primarily influenced by quarterly revenue growth, advancements in its AI diagnostic platform, strategic partnerships with pharmaceutical companies, and broader market sentiment toward the healthcare and AI sectors.

Is Tempus AI profitable?

As of the latest 2025 financial reports, Tempus AI is not yet profitable on a net income basis, though it has shown significant improvement in narrowing its losses and increasing its gross profit margins.

What is the market cap of Tempus AI?

As of April 2026, the market capitalization of Tempus AI is approximately $9.96 billion.